Log in
Enquire now
CatalYm

CatalYm

CatalYm is an innovative immunotherapies developer for cancer patients founded in 2016.

OverviewStructured DataIssuesContributors

Contents

catalym.com
Is a
Company
Company
Funding round
Funding round
Organization
Organization

Company attributes

Industry
Healthcare
Healthcare
Health technology
Health technology
Biotechnology
Biotechnology
Internal medicine
Internal medicine
Immunotherapy
Immunotherapy
Cancer immunotherapy
Cancer immunotherapy
Oncology
Oncology
Life science
Life science
...
Location
Germany
Germany
B2X
B2B
B2B
Number of Employees (Ranges)
11 – 50
Email Address
Phone Number
Investors
Brandon Capital Partners
Brandon Capital Partners
Forbion Capital Partners
Forbion Capital Partners
BioGeneration Ventures
BioGeneration Ventures
Bayern Kapital
Bayern Kapital
Coparion
Coparion
Vesalius Biocapital III
Vesalius Biocapital III
Jeito Capital
Jeito Capital
Brandon Capital
Brandon Capital
...
Founded Date
2016
Total Funding Amount (USD)
160,000,000
Latest Funding Round Date
November 1, 2022
Also Known As
CataIYm
Latest Funding Type
Series C
Series C
Country
Germany
Germany
Headquarters
Munich
Munich

Funding Round attributes

Funding Type
Series B
Series B
Funded Company
CatalYm
CatalYm
Funding Round Amount (USD)
52,000,000
Funding Round Date
November 1, 2022

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
52,000,000
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like CatalYm

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.